The Lancet Oncology in conversation with

Madeline Pe on the SISAQOL initiative


Listen Later

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00157-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

...more
View all episodesView all episodes
Download on the App Store

The Lancet Oncology in conversation withBy The Lancet Group

  • 5
  • 5
  • 5
  • 5
  • 5

5

1 ratings


More shows like The Lancet Oncology in conversation with

View all
Global News Podcast by BBC World Service

Global News Podcast

7,710 Listeners

NEJM This Week by NEJM Group

NEJM This Week

321 Listeners

The Daily by The New York Times

The Daily

112,351 Listeners

OncoPharm by John Bossaer

OncoPharm

185 Listeners

Harrison's PodClass: Internal Medicine Cases and Board Prep by AccessMedicine

Harrison's PodClass: Internal Medicine Cases and Board Prep

364 Listeners

anything goes with emma chamberlain by emma chamberlain

anything goes with emma chamberlain

62,568 Listeners

The Uromigos by The Uromigos

The Uromigos

56 Listeners

The Lancet Voice by The Lancet Group

The Lancet Voice

22 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

1 Listeners

The Lancet in conversation with by The Lancet Group

The Lancet in conversation with

0 Listeners

The Lancet Haematology in conversation with by The Lancet Group

The Lancet Haematology in conversation with

0 Listeners

The Lancet Gastroenterology & Hepatology in conversation with by The Lancet Group

The Lancet Gastroenterology & Hepatology in conversation with

1 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

EHA Unplugged by European Hematology Association

EHA Unplugged

1 Listeners

The Lancet Rheumatology in conversation with by The Lancet Group

The Lancet Rheumatology in conversation with

0 Listeners

The Lancet Regional Health in conversation with by The Lancet Group

The Lancet Regional Health in conversation with

0 Listeners

What Did You Do Yesterday? with Max Rushden & David O'Doherty by Keep It Light Media

What Did You Do Yesterday? with Max Rushden & David O'Doherty

213 Listeners

The Lancet Primary Care in conversation with by The Lancet Group

The Lancet Primary Care in conversation with

0 Listeners

The Lancet Regional Health Americas in conversation with by The Lancet Group

The Lancet Regional Health Americas in conversation with

0 Listeners